Preventive Effect of a Dietary Supplement With Two Probiotic Limosilactobacillus Reuteri Strains on Excessive Crying and Colic in Healthy Newborns. (ProtectPrevent)

Universitair Ziekenhuis Brussel

Status: Not yet enrolling

Conditions: Eczema Atopic Dermatitis; Healthy Infants; Colic

Treatments: Dietary Supplement: Two probiotic Limosilactobacillus reuteri strains; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT07347743

Prot-Prev

Details and patient eligibility

About

This study aims to demonstrate that a dietary supplement, which contains two strains (DSM 17938 and BG-R46TM) of the probiotic L. reuteri is safe, well tolerated and able to reduce the incidence of colic and excessive crying/fussiness in healthy infants. Additionally, the study aims to investigate if children with this probiotic supplement have better stool characteristics and a more beneficial composition of the fecal and skin flora than children given a placebo during the first 3 months of life.

Full description

This study is a double-blind, randomized, placebo-controlled trial conducted at UZ Brussel to evaluate the safety and preventive efficacy of a dietary supplement containing two probiotic strains, Limosilactobacillus reuteri DSM 17938 and BG-R46™, on excessive crying and the development of infantile colic in healthy newborns.

Recent systematic reviews and meta-analyses have shown that supplementation with L. reuteri DSM 17938 significantly reduces crying and fussing time in infants. A novel formulation combining DSM 17938 with BG-R46™ was developed to achieve a potentially enhanced effect on infant distress symptoms. This study investigates whether early supplementation, initiated within the first week of life, is safe and effective during the first three months of life.

Healthy, full-term infants (≥37 weeks' gestation) aged 1-14 days at inclusion are eligible. Participants are randomized to receive either placebo plus vitamin D (400 IU) or L. reuteri DSM 17938 and BG-R46™ plus vitamin D (400 IU) for a maximum of 98 days, until approximately 3 months of age.

Study visits include a baseline visit (day 1-14), a midway visit at 6 weeks, an end-of-intervention visit at 3 months, and a long-term follow-up at 1 year. Additional telephone contacts are triggered by infant day diaries.

The primary outcomes are peak crying and fussing time at 6 weeks of age and the occurrence of infantile colic during the first 3 months of life. Secondary outcomes include infant quality of life (ITQOL™), parental stress, parental satisfaction, crying and fussiness patterns, and the presence of atopic dermatitis. Exploratory outcomes assess changes in the intestinal microbiome, stool characteristics, biomarkers, growth, and allergy-related parameters.

The primary hypothesis is that daily supplementation with L. reuteri DSM 17938 and BG-R46™ reduces the incidence of infantile colic and peak crying time at 6 weeks. Secondary hypotheses propose microbiome modulation leading to reduced distress, improved infant quality of life, and lower parental stress.

Enrollment: 768 estimated patients

Sex: All

Ages: 1 to 14 days old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Infant is born at the maternity ward of UZ Brussel with a gestational age of ≥37 weeks.
2. Infant is healthy at the time of pre-examination.
3. Infant is aged between 1 and 14 days old at the time of inclusion.
4. Legal guardian(s) are able and willing to follow the study instructions
5. Infant is suitable for participation in the study according to the investigator/ study personnel
6. Legal guardian(s) willing to refrain products containing probiotics for their infant, from baseline (visit 1) throughout the study period (visit 3).
7. Informed written consent given by parent / legal guardian

Exclusion criteria

1. No legal guardian's command of any local language
2. Infant with a major congenital anomaly (i.e. anal atresia, trisomy 21) or suspicion of any chronic disorder or disease (i.e. Hirschsprung's disease, metabolic disorder)
3. Infant is suffering from congenital or acquired immunodeficiency
4. Infant is suffering from an infection at the time of pre-examination or previous 7 days
5. Infant is admitted post-partum to the neonatal intensive care unit
6. Infant is not suitable for participation in the study according to the study personnel´s opinion

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

768 participants in 2 patient groups, including a placebo group

Control group

Placebo Comparator group

Description:

The control groups gets no Limosilactobacillus reuteri

Treatment:

Dietary Supplement: Placebo

Intervention group

Experimental group

Description:

The intervention group gets the two probiotic Limosilactobacillus reuteri strains

Treatment:

Dietary Supplement: Two probiotic Limosilactobacillus reuteri strains